Cargando…

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease

BACKGROUND: A clinical decision support tool (CDST) has been validated for predicting treatment effectiveness of vedolizumab (VDZ) in Crohn’s disease. AIM: To assess the utility of this CDST for predicting exposure‐efficacy and disease outcomes. METHODS: Using data from three independent datasets (G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dulai, Parambir S., Amiot, Aurelien, Peyrin‐Biroulet, Laurent, Jairath, Vipul, Serrero, Melanie, Filippi, Jerome, Singh, Siddharth, Pariente, Benjamin, Loftus, Edward V., Roblin, Xavier, Kane, Sunanda, Buisson, Anthony, Siegel, Corey A., Bouhnik, Yoram, Sandborn, William J., Lasch, Karen, Rosario, Maria, Feagan, Brian G., Bojic, Daniela, Trang‐Poisson, Caroline, Shen, Bo, Altwegg, Romain, Sands, Bruce E., Colombel, Jean‐Frederic, Carbonnel, Franck
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Optimising Vedolizumab in Crohn's Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028036/ https://www.ncbi.nlm.nih.gov/pubmed/31867766 http://dx.doi.org/10.1111/apt.15609

Ejemplares similares

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation
por: Osterman, Mark T., et al.
Publicado: (2019)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Early Intervention With Vedolizumab and Longer-term Surgery Rates in Crohn’s Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programmes
por: Dulai, Parambir S, et al.
Publicado: (2020)

A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II
por: Lenti, Marco Vincenzo, et al.
Publicado: (2021)

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
por: Sandborn, William J, et al.
Publicado: (2019)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
por: Sandborn, W. J., et al.
Publicado: (2018)

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
por: Vande Casteele, N., et al.
Publicado: (2017)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study
por: Pugliese, Daniela, et al.
Publicado: (2022)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme
por: Danese, Silvio, et al.
Publicado: (2020)

Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2022)

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
por: Feagan, B. G., et al.
Publicado: (2016)

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020)

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies
por: Dulai, Parambir S., et al.
Publicado: (2019)

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease
por: Holmer, Ariela K., et al.
Publicado: (2020)

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
por: Narula, Neeraj, et al.
Publicado: (2019)

Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn’s Disease
por: Dulai, Parambir S, et al.
Publicado: (2022)

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials
por: Feagan, Brian G, et al.
Publicado: (2019)

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis
por: Faleck, David M., et al.
Publicado: (2019)

Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes
por: Koliani-Pace, Jenna L, et al.
Publicado: (2019)

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
por: Schreiber, Stefan, et al.
Publicado: (2018)

Crohn's disease of the gastrointestinal tract /
por: Schachter, Howard
Publicado: (1980)

Impact of patient characteristics on the clinical efficacy of mongersen (GED‐0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
por: Monteleone, G., et al.
Publicado: (2016)

Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2
por: Feagan, Brian G, et al.
Publicado: (2018)

Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
por: Rundquist, Sara, et al.
Publicado: (2020)

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
por: Colombel, J.‐F., et al.
Publicado: (2016)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Systematic review: Safety of balloon assisted enteroscopy in Crohn’s disease
por: Arulanandan, Ahilan, et al.
Publicado: (2016)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022)

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2022)

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kh1qrptt74k8ogtfnekfhhtd0i